Status:
COMPLETED
Effect of Exenatide on 24-Hour Blood Glucose Profile Compared With Placebo in Patients With Type 2 Diabetes
Lead Sponsor:
AstraZeneca
Collaborating Sponsors:
Eli Lilly and Company
Conditions:
Type 2 Diabetes Mellitus
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to test the hypothesis that in patients with type 2 diabetes, the addition of exenatide will result in lower time-averaged serum glucose during a 24-hour period, compared ...
Eligibility Criteria
Inclusion
- Subject has an HbA1c between 7.0% and 10.0%, inclusive.
- Subject has a body mass index (BMI) \>25 kg/m\^2 and \<50 kg/m\^2.
- Subject is on a stable dose of metformin or metformin plus a thiazolidinedione.
Exclusion
- Subject has been treated with any of the following medications: \*exogenous insulin for more than 1 week within 3 months of screening, \*sulfonylureas or meglitinides within 2 months of screening, \*alpha-glucosidase inhibitors within 2 months of screening, \*pramlintide acetate injection within 2 months of screening.
- Subject has received exenatide, GLP-1 analogs, DPP-IV inhibitors, or has participated in this study previously.
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2007
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00241423
Start Date
October 1 2005
End Date
June 1 2007
Last Update
February 23 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Washington D.C., District of Columbia, United States
2
Research Site
San Antonio, Texas, United States